1.1 Denosumab is recommended as an option for preventing skeletal-related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with bone metastases from breast cancer and from solid tumours other than prostate if:
bisphosphonates would otherwise be prescribed and
the manufacturer provides denosumab with the discount agreed in the patient access scheme.
1.2 Denosumab is not recommended for preventing skeletal-related events in adults with bone metastases from prostate cancer.
1.3 Adults with bone metastases from solid tumours currently receiving denosumab for the prevention of skeletal-related events that is not recommended according to 1.1 and 1.2 should be able to continue treatment until they and their clinician consider it appropriate to stop.